Skip to menu Skip to content Skip to footer

2023

Journal Article

68Ga-PSMA-PET/CT in addition to mpMRI in men undergoing biopsy during active surveillance for low- to intermediate-risk prostate cancer: study protocol for a prospective cross-sectional study

Gondoputro, William, Doan, Paul, Katelaris, Athos, Scheltema, Matthijs J., Geboers, Bart, Agrawal, Shikha, Liu, Zhixin, Yaxley, John, Savdie, Richard, Rasiah, Kris, Frydenberg, Mark, Roberts, Matthew J., Malouf, David, Wong, David, Shnier, Ron, Delprado, Warick, Emmett, Louise, Stricker, Phillip D. and Thompson, James (2023). 68Ga-PSMA-PET/CT in addition to mpMRI in men undergoing biopsy during active surveillance for low- to intermediate-risk prostate cancer: study protocol for a prospective cross-sectional study. Translational Andrology and Urology, 12 (10), 1598-1606. doi: 10.21037/tau-22-708

68Ga-PSMA-PET/CT in addition to mpMRI in men undergoing biopsy during active surveillance for low- to intermediate-risk prostate cancer: study protocol for a prospective cross-sectional study

2023

Journal Article

Prostate volume analysis in image registration for prostate cancer care: a verification study

Bugeja, Jessica M., Mehawed, Georges, Roberts, Matthew J., Rukin, Nicholas, Dowling, Jason and Murray, Rebecca (2023). Prostate volume analysis in image registration for prostate cancer care: a verification study. Physical and Engineering Sciences in Medicine, 46 (4), 1-12. doi: 10.1007/s13246-023-01342-4

Prostate volume analysis in image registration for prostate cancer care: a verification study

2023

Journal Article

High risk clear cell renal cell carcinoma microenvironments contain protumour immunophenotypes lacking specific immune checkpoints

Raghubar, Arti M., Matigian, Nicholas A., Crawford, Joanna, Francis, Leo, Ellis, Robert, Healy, Helen G., Kassianos, Andrew J., Ng, Monica S. Y., Roberts, Matthew J., Wood, Simon and Mallett, Andrew J. (2023). High risk clear cell renal cell carcinoma microenvironments contain protumour immunophenotypes lacking specific immune checkpoints. npj Precision Oncology, 7 (1) 88, 1-9. doi: 10.1038/s41698-023-00441-5

High risk clear cell renal cell carcinoma microenvironments contain protumour immunophenotypes lacking specific immune checkpoints

2023

Journal Article

DIPPER trial protocol: A multi‐centre, randomised trial of salvage radiotherapy versus surveillance for biochemical recurrence after radical prostatectomy (ANZUP 2002)

Roberts, Matthew J., Conduit, Ciara, Davis, Ian D., Effeney, Rachel M., Williams, Scott, Martin, Jarad M., Hofman, Michael S., Hruby, George, Eapen, Renu, Gianacas, Chris, Papa, Nathan, Lourenço, Richard De Abreu, Dhillon, Haryana M, Allen, Ray, Fontela, Antoinette, Kaur, Baldeep, Emmett, Louise and The Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) (2023). DIPPER trial protocol: A multi‐centre, randomised trial of salvage radiotherapy versus surveillance for biochemical recurrence after radical prostatectomy (ANZUP 2002). BJU International, 133 (S3), 39-47. doi: 10.1111/bju.16158

DIPPER trial protocol: A multi‐centre, randomised trial of salvage radiotherapy versus surveillance for biochemical recurrence after radical prostatectomy (ANZUP 2002)

2023

Journal Article

Clinical impact of Prostate-Specific Membrane Antigen Positron Emission Tomography (PET) on intensification or deintensification of advanced renal cell carcinoma management

Pathmanathan, Shivanshan, Tariq, Arsalan, Pearce, Adam, Rhee, Handoo, Kyle, Samuel, Raveenthiran, Sheliyan, Wong, David, McBean, Rhiannon, Marsh, Phillip, Goodman, Steven, Dhiantravan, Nattakorn, Esler, Rachel, Dunglison, Nigel, Navaratnam, Anojan, Yaxley, John, Thomas, Paul, Pattison, David A., Goh, Jeffrey C., Gan, Chun Loo and Roberts, Matthew J. (2023). Clinical impact of Prostate-Specific Membrane Antigen Positron Emission Tomography (PET) on intensification or deintensification of advanced renal cell carcinoma management. European Journal of Nuclear Medicine and Molecular Imaging, 51 (1), 295-303. doi: 10.1007/s00259-023-06380-4

Clinical impact of Prostate-Specific Membrane Antigen Positron Emission Tomography (PET) on intensification or deintensification of advanced renal cell carcinoma management

2023

Journal Article

Uro-symphyseal fistula: a systematic review to inform a contemporary, evidence-based management framework

Patel, Nishal, Mehawed, Georges, Dunglison, Nigel, Esler, Rachel, Navaratnam, Anojan, Yaxley, John, Chung, Eric, Tse, Vincent and Roberts, Matthew J. (2023). Uro-symphyseal fistula: a systematic review to inform a contemporary, evidence-based management framework. Urology, 178, 1-8. doi: 10.1016/j.urology.2023.05.002

Uro-symphyseal fistula: a systematic review to inform a contemporary, evidence-based management framework

2023

Conference Publication

PRIMARY2 Trial Protocol: Phase III, multicentre, randomised controlled trial investigating the additive diagnostic value of [68Ga]Ga-PSMA-11 PET/CT in men with negative/equivocal MRI in the diagnosis of clinically significant prostate cancer

Buteau, James, Moon, Daniel, Fahey, Michael, Roberts, Matthew, Thompson, James, Murphy, Declan G., Papa, Nathan, Mitchell, Catherine, Kasivisvanathan, Veeru, Stricker, Phillip, O'Brien, Jonathan, Counter, William, Sharma, Gaurav, Agrawal, Shikha, Ho, Bao, Dilulio, Juliana, Lindeman, William, De Abreu, Lourenco Richard, Dhillon, Haryana M., Hofman, Michael S. and Emmett, Louise (2023). PRIMARY2 Trial Protocol: Phase III, multicentre, randomised controlled trial investigating the additive diagnostic value of [68Ga]Ga-PSMA-11 PET/CT in men with negative/equivocal MRI in the diagnosis of clinically significant prostate cancer. 2023 ANZUP Annual Scientific Meeting, Bouncing Back, Melbourne, VIC, Australia, 9-11 July 2023. Hoboken, NJ, United States: Wiley.

PRIMARY2 Trial Protocol: Phase III, multicentre, randomised controlled trial investigating the additive diagnostic value of [68Ga]Ga-PSMA-11 PET/CT in men with negative/equivocal MRI in the diagnosis of clinically significant prostate cancer

2023

Conference Publication

Can artificial intelligence devise surveillance regimens for testicular cancer?

Collin, Harry, Keogh, Kandice and Roberts, Matthew (2023). Can artificial intelligence devise surveillance regimens for testicular cancer?. 2023 ANZUP Annual Scientific Meeting, Bouncing Back, Melbourne, VIC, Australia, 9-11 July 2023. Hoboken, NJ, United States: Wiley.

Can artificial intelligence devise surveillance regimens for testicular cancer?

2023

Conference Publication

Dr Bot - Does AI provide quality information to prostate cancer patients?

Collin, Harry, Keogh, Kandice and Roberts, Matthew (2023). Dr Bot - Does AI provide quality information to prostate cancer patients?. 2023 ANZUP Annual Scientific Meeting, Bouncing Back, Melbourne, VIC, Australia, 9-11 July 2023. Hoboken, NJ, United States: Wiley.

Dr Bot - Does AI provide quality information to prostate cancer patients?

2023

Journal Article

Trends and variation in prostate cancer diagnosis via transperineal biopsy in Australia and New Zealand

O' Callaghan, Michael E., Roberts, Matthew, Grummet, Jeremy, Mark, Stephen, Gilbourd, Daniel, Frydenberg, Mark, Millar, Jeremy and Papa, Nathan (2023). Trends and variation in prostate cancer diagnosis via transperineal biopsy in Australia and New Zealand. Urologic Oncology: Seminars and Original Investigations, 41 (7), 324.e13-324.e20. doi: 10.1016/j.urolonc.2023.05.011

Trends and variation in prostate cancer diagnosis via transperineal biopsy in Australia and New Zealand

2023

Conference Publication

Initial diagnostic accuracy of FDG-PET compared to PSMA-PET for newly diagnosed high risk prostate cancer prior to treatment: FIND Trial

Roberts, Matthew, Roberts, Natasha, Harley, Simon, Cullen, Karla, Pelecanos, Anita, Vela, Ian, Yaxley, John, Kuchel, Anna, Dhiantravan, Nattakorn, Thomas, Paul and Pattison, David (2023). Initial diagnostic accuracy of FDG-PET compared to PSMA-PET for newly diagnosed high risk prostate cancer prior to treatment: FIND Trial. 2023 ANZUP Annual Scientific Meeting, Bouncing Back, Melbourne, VIC, Australia, 9-11 July 2023. Hoboken, NJ, United States: Wiley.

Initial diagnostic accuracy of FDG-PET compared to PSMA-PET for newly diagnosed high risk prostate cancer prior to treatment: FIND Trial

2023

Journal Article

A novel risk calculator incorporating clinical parameters, multiparametric magnetic resonance imaging, and prostate-specific membrane antigen positron emission tomography for prostate cancer risk stratification before transperineal prostate biopsy

Kelly, Brian D., Ptasznik, Gideon, Roberts, Matthew J., Doan, Paul, Stricker, Phillip, Thompson, James, Buteau, James, Chen, Kenneth, Alghazo, Omar, O'Brien, Jonathan S., Hofman, Michael S., Frydenberg, Mark, Lawrentschuk, Nathan, Lundon, Dara, Murphy, Declan G., Emmett, Louise and Moon, Daniel (2023). A novel risk calculator incorporating clinical parameters, multiparametric magnetic resonance imaging, and prostate-specific membrane antigen positron emission tomography for prostate cancer risk stratification before transperineal prostate biopsy. European Urology Open Science, 53, 90-97. doi: 10.1016/j.euros.2023.05.002

A novel risk calculator incorporating clinical parameters, multiparametric magnetic resonance imaging, and prostate-specific membrane antigen positron emission tomography for prostate cancer risk stratification before transperineal prostate biopsy

2023

Conference Publication

Lu-PSMA Therapy - Practical considerations for urologists

Collin, Harry, Keogh, Kandice and Roberts, Matthew (2023). Lu-PSMA Therapy - Practical considerations for urologists. 2023 ANZUP Annual Scientific Meeting, Bouncing Back, Melbourne, VIC, Australia, 9-11 July 2023. Hoboken, NJ, United States: Wiley.

Lu-PSMA Therapy - Practical considerations for urologists

2023

Journal Article

Vitamin C as an adjunct to methenamine hippurate use after ALTAR: ego or evidence‐based?

Keogh, Kandice, Collin, Harry, Dowling, Caroline and Roberts, Matthew J. (2023). Vitamin C as an adjunct to methenamine hippurate use after ALTAR: ego or evidence‐based?. BJU International, 133 (S3), 6-7. doi: 10.1111/bju.16096

Vitamin C as an adjunct to methenamine hippurate use after ALTAR: ego or evidence‐based?

2023

Journal Article

Periurethral abscess etiology, risk factors, treatment options, and outcomes: A systematic review

Tariq, Arsalan, Stewart, Adam G., Desai, Devang J., Britton, Sumudu, Dunglison, Nigel, Esler, Rachel and Roberts, Matthew J. (2023). Periurethral abscess etiology, risk factors, treatment options, and outcomes: A systematic review. Current Urology, 17 (2), 100-108. doi: 10.1097/cu9.0000000000000159

Periurethral abscess etiology, risk factors, treatment options, and outcomes: A systematic review

2023

Conference Publication

Adding mitomycin (MM) to bacillus Calmette-Guerin (BCG) as adjuvant intravesical therapy for high-risk, non-muscle-invasive urothelial bladder cancer (NMIBC)

Hayne, Dickon, Stockler, Martin R., Martin, Andrew James, McCombie, Steve P., Zebic, Danka Sinikovic, Bastick, Patricia A., Beardsley, Emma Kate, Frydenberg, Mark, Green, William, Grummet, Jeremy, Hawks, Cynthia, Ischia, Joseph, Mitterdorfer, Andrew, Patel, Manish, Roberts, Matthew, Sengupta, Shomik, Srivastav, Ratnesh Kumar, Redfern, Andrew David and Davis, Ian D. (2023). Adding mitomycin (MM) to bacillus Calmette-Guerin (BCG) as adjuvant intravesical therapy for high-risk, non-muscle-invasive urothelial bladder cancer (NMIBC). Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL USA, 2-6 June 2023. Philadelphia, PA USA: Lippincott Williams & Wilkins. doi: 10.1200/JCO.2023.41.16_suppl.TPS4617

Adding mitomycin (MM) to bacillus Calmette-Guerin (BCG) as adjuvant intravesical therapy for high-risk, non-muscle-invasive urothelial bladder cancer (NMIBC)

2023

Journal Article

Treatment de‐intensification for low‐risk biochemical recurrence after radical prostatectomy: rational or risky?

Roberts, Matthew J., Hruby, George, Kneebone, Andrew, Martin, Jarad M., Williams, Scott G., Frydenberg, Mark, Murphy, Declan G., Namdarian, Ben, Yaxley, John W., Hofman, Michael S., Davis, Ian D. and Emmett, Louise (2023). Treatment de‐intensification for low‐risk biochemical recurrence after radical prostatectomy: rational or risky?. BJU International, 132 (2), 146-148. doi: 10.1111/bju.16086

Treatment de‐intensification for low‐risk biochemical recurrence after radical prostatectomy: rational or risky?

2023

Journal Article

Synchronous versus independent reading of PSMA‐PET and MRI to improve diagnosis for prostate cancer

Doan, Paul, Counter, William, Papa, Nathan, Sheehan‐Dare, Gemma, Ho, Bao, Lee, Jonathan, Liu, Victor, Thompson, James E., Agrawal, Shikha, Roberts, Matthew J., Buteau, James, Hofman, Michael S., Moon, Daniel, Lawrentschuk, Nathan, Murphy, Declan, Stricker, Phillip D. and Emmett, Louise (2023). Synchronous versus independent reading of PSMA‐PET and MRI to improve diagnosis for prostate cancer. BJU International, 131 (5), 588-595. doi: 10.1111/bju.15929

Synchronous versus independent reading of PSMA‐PET and MRI to improve diagnosis for prostate cancer

2023

Journal Article

Pubic symphysis septic arthritis due to urosymphyseal fistula: conservative management can work

Mehawed, Georges, Ranasinghe, Sachinka and Roberts, Matthew J. (2023). Pubic symphysis septic arthritis due to urosymphyseal fistula: conservative management can work. Urology Case Reports, 47 102356, 1-3. doi: 10.1016/j.eucr.2023.102356

Pubic symphysis septic arthritis due to urosymphyseal fistula: conservative management can work

2023

Conference Publication

PRIMARY2: A phase III, multi-centre, randomised controlled trial investigating the additive diagnostic value of [<sup>68</sup>Ga]Ga-PSMA-11 PET/CT in men with negative/equivocal MRI in the diagnosis of clinically significant prostate cancer

Buteau, James Patrick, Moon, Daniel, Fahey, Michael T., Roberts, Matthew, Thompson, James, Murphy, Declan G., Papa, Nathan, Mitchell, Catherine, Kasivisvanathan, Veeru, Stricker, Phillip, O'Brien, Jonathan, Counter, William, Sharma, Gaurav, Agrawal, Shikha, Ho, Bao, Yeung, Theresa, De Abreu Lourenço, Richard, Dhillon, Haryana M., Hofman, Michael S and Emmett, Louise (2023). PRIMARY2: A phase III, multi-centre, randomised controlled trial investigating the additive diagnostic value of [68Ga]Ga-PSMA-11 PET/CT in men with negative/equivocal MRI in the diagnosis of clinically significant prostate cancer. 2023 ASCO Genitourinary Cancers Symposium, San Francisco, CA United States, 16-18 February 2023. Alexandria, VA United States: American Society of Clinical Oncology. doi: 10.1200/jco.2023.41.6_suppl.tps397

PRIMARY2: A phase III, multi-centre, randomised controlled trial investigating the additive diagnostic value of [<sup>68</sup>Ga]Ga-PSMA-11 PET/CT in men with negative/equivocal MRI in the diagnosis of clinically significant prostate cancer